HC Wainwright Reaffirms Buy Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $73.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 64.12% from the stock's previous close. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q1 2025 earnings at ($0.80) EPS, Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($1.59) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at $1.52 EPS, FY2026 earnings at $1.52 EPS, FY2027 earnings at $4.14 EPS, FY2027 earnings at $4.14 EPS, FY2028 earnings at $5.10 EPS and FY2029 earnings at $6.29 EPS.

TARS has been the topic of a number of other research reports. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Guggenheim restated a "buy" rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays lifted their target price on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a research report on Monday, January 27th. Finally, The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $61.33.

Remove Ads

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS traded up $0.93 during trading on Wednesday, reaching $44.48. The stock had a trading volume of 845,617 shares, compared to its average volume of 650,148. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.28. The stock has a market cap of $1.71 billion, a PE ratio of -11.67 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The business has a fifty day moving average price of $50.97 and a 200-day moving average price of $43.13.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. On average, equities analysts forecast that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Crowley Wealth Management Inc. purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $25,000. GF Fund Management CO. LTD. acquired a new position in Tarsus Pharmaceuticals in the fourth quarter worth about $44,000. R Squared Ltd acquired a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $53,000. FMR LLC boosted its stake in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after acquiring an additional 3,537 shares during the period. Finally, Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $166,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.